REMINDER: As announced last month, PDCI and its research partners are studying the private payer product listing agreement (PLA) landscape in Canada by surveying pharmaceutical manufacturers and private payers about their ... Read More
News & Events
05
May2020
16
Apr2020
PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study!
The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders ... Read More
14
Apr2020
Bryan Ferguson, Editor, Insights Within 1-2 weeks, 1 million people laid off in March will begin to lose their health benefits.Laid-off patients who previously had access to drug insurance will now find themselves with no coverage or, if coverage continues, with reduced financial means to afford copayments and ... Read More
06
Apr2020
PDCI Market Access Inc. (PDCI), Canada’s leading pricing, reimbursement and health economics consultancy, is pleased to announce its strategic partnership with Mark Fleming. Mark is joining PDCI as Strategic Advisor supporting PDCI’s pricing, market access and policy research activities.
... Read More
31
Mar2020
PDCI Acquires Exclusive License for TELUS Health’s Market Access Toolkit Including INSIGHTS Magazine and Census of Insurers
/ News, PDCI, What's New
We are excited to announce that PDCI Market Access Inc. (“PDCI”) has entered into an Exclusive License Agreement for the rights to the Market Access Toolkit from TELUS Health Solutions Inc.
The Market Access Toolkit has been a critical resource to the pharmaceutical industry for more than 20 years. First developed ... Read More
26
Mar2020
Government Authorizes Temporary Compulsory Liscensing in Emergency Legislation for Products Needed to Respond to the COVID-19 Emergency
/ News
Bill C-13 is the government’s emergency legislation in response to the COVID-19 pandemic. The bill includes amendments to the Patent Act by adding a new section (19.4) which includes the following:
Empowers the Minister of Health to require the Commissioner of Patents to authorize any person specified by the ... Read More
19
Mar2020
PMPRB Has Now Published Submissions Received as Part of its Draft Guidelines Consultation
/ PDCI, PMPRB, What's New
The full list of submissions can be found here under the Submissions tab at the bottom of the page.
Background: On November 21, 2019, the PMPRB published its draft Guidelines and launched a public consultation as a step towards implementing the recently amended Patented Medicines Regulations. The PMPRB ... Read More
16
Mar2020
Good Afternoon,
At PDCI Market Access Inc. (“PDCI”) we are committed to providing high quality services and deliverables to our clients. We also recognize the important responsibility we all have to prevent the spread of the COVID-19 outbreak.
Based on the information received to date, we are currently implementing the following accommodations ... Read More
10
Mar2020
PMPRB Cancellation of March 18th Policy Forum
The Patented Medicines Prices Review Board (PMPRB) has announced the cancellation of its Policy Forum expected to be held on March 18th, 2020 amid the evolving COVID-19 situation.
In order to provide stakeholders with an opportunity to convey information that may ... Read More
26
Feb2020
PDCI is pleased to inform you of the launch of its podcast series, Between the Lines. Between the Lines invites thought leaders and industry experts to share their insights about the trends and controversies that are shaping the pharmaceutical policy ... Read More